PathAI

We’re attending the upcoming #SITC2024 meeting in Houston, TX and will be presenting novel findings utilizing the recently launched #AIPathology tool, PathExplore™ Fibrosis. Learn more about the #AI development of this unique tool for analyzing the fibrotic microenvironment directly from H&E whole slide images and how it was utilized in real-world research for quantifying #fibrosis, fibrotic features, collagen, and more. Visit our posters presented by Matthew Bronnimann on Saturday, Nov 9, 2024 # 1378: Stromal collagen features from H&E-stained whole slide images are associated with lymphocyte infiltration and survival following checkpoint inhibition in patients with non-small cell lung cancer # 88: Machine learning-based collagen fiber quantification enables analysis of the pancreatic cancer tumor microenvironment directly from hematoxylin and eosin-stained whole slide images Learn More: https://lnkd.in/evxurVfg PathExplore™ Fibrosis is for research use only. Not for use in diagnostic procedures. #SITC #SITC24 #Pathology #digitalpathology

We sat down with VP of Product & Translational Research, Ben Glass, to discuss how #AI-powered #pathology is revolutionizing fibrosis quantification in #oncology and to learn more about the development of PathAI’s latest product: PathExplore™ Fibrosis Learn more about the product and #demo today: https://lnkd.in/evxurVfg As #precisionmedicine advances, understanding novel biomarkers like fibrosis has potential to optimize cancer therapies and predict patient outcomes. #Fibrosis #biomarkers, such as fiber and collagen parameters, play a significant role in the tumor microenvironment, in some cases correlating with disease progression and treatment response. However, traditional fibrosis quantification methods often face limitations due to the need for specialized microscopy and challenges in scalability. In our discussion, Ben sheds light on how PathExplore Fibrosis offers a cutting-edge solution by bringing precision, scalability, and reproducibility to fibrosis assessment. #digitalpathology #AIPathology #biotech #oncology #cancerresearch #drugdevelopment PathExplore™ Fibrosis is for research use only. Not for use in diagnostic procedures.

New Friends of Cancer Research findings in American Society of Clinical Oncology (ASCO) #jcooa examine variability in outputs from homologous recombination deficiency (HRD) assays assessing a common sample set. HRD is a biomarker used to determine eligibility for Poly ADP-ribose Polymerase Inhibitors (PARPi) to treat high-grade serous ovarian carcinoma (HGSOC).      The findings demonstrate variability in HRD results across assays, suggesting the need for consistent and aligned strategies in biomarker selection for clinical trials and clinical decision-making in oncology drug development. Read the full publication here: bit.ly/3YSeTck   This manuscript is the final output from Friends HRD Project, which aims to answer the question: Does Homologous Recombination Deficiency (HRD) status differ across HRD assays and what contributes to variability? Learn more about Friends HRD Project here: https://lnkd.in/dta-3D5y     #HRDFriends    Thank you to our coauthors: Hillary Andrews, PhD, Lisa McShane, Elis C. Kohn, Rebecca Arend, Chris Karlovich, Kaitlyn Kincaid, Douglas Laird, Ming-Chung Li, Ethan Sokol, Elizabeth R. Starks, Shulin Bi, Lauren Brunner, Alyssa Chapman, Li Chen, Tommaso Coletta, Yuan Ding, Bailee Dover, McKenzie Foxall, Mohit Gupta, Zan Halford, Andrea G. Kahn, Nikita Kotlov, Yi-Hsuan Lucy Lai, Alexander J. Lazar, Wenjie Li, Brittany Avin McKelvey, Hyunjun Nam, Sarabjot Pabla, Pegah Safabakhsh, Daniel Saul, Albrecht Stenzinger, Timothy J. Taxter, M.D., Zhiwei Zhang, Yingdong Zhao, ShiPing Zou, Mark Stewart, Jeff Allen.   This work is possible through a large-scale partnership. Thank you to the following partners: Friends of Cancer Research, National Cancer Institute (NCI), University of Alabama at Birmingham, Frederick National Laboratory for Cancer Research, Pfizer, Foundation Medicine, Invitae, Amoy Diagnostics, PathAI, SOPHiA GENETICS, Illumina, Thermo Fisher Scientific, Diagnostic Laboratory Services, BostonGene, ACT Genomics, The University of Texas MD Anderson Cancer Center, Burning Rock Dx, NeoGenomics Laboratories, Labcorp Oncology (OmniSeq), Guardant Health, Bionano Genomics, Inc., University Hospital Heidelberg (UKHD), Tempus AI, Pillar Biosciences Incorporated. 

Today, we announced the launch of our latest #AIPathology tool, PathExplore™ Fibrosis- an AI-driven breakthrough that brings powerful #fibrosis, collagen, and fiber quantification directly from your standard H&E whole-slide images. See it in action: https://lnkd.in/evxurVfg In #cancerresearch, fibrosis and collagen fibers are increasingly recognized as critical biomarkers linked to disease progression, immune response, and treatment outcomes. Traditional methods for quantifying these features often rely on labor-intensive techniques that are difficult to scale. PathExplore™ Fibrosis changes that. Powered by #AI, it seamlessly integrates into routine pathology workflows—no special stains, no extra equipment—just precise, scalable analysis directly from your H&E slides. - Effortlessly Scalable: Perform rapid, large-scale fibrosis and collagen analysis, speeding up biomarker discovery and research timelines. - Deep Tumor Insights with Deep Learning: Quantify fibrotic features with precision, offering a clearer understanding of tumor biology and therapeutic impact. - Optimized for your routine H&E Samples: Easily integrate into your existing processes without the need for complex microscopy or custom staining techniques. PathExplore™ Fibrosis is for research use only. Not for use in diagnostic procedures. #Pathology #biotech #digitalpathology #oncology

🚀 We're proud to launch PathExplore™ Fibrosis, a groundbreaking #AIPathology algorithm that quantifies fibrosis, collagen, and fiber morphology directly from H&E whole-slide images. This revolutionary tool provides a unique view into the tumor microenvironment (#TME), empowering researchers & drug developers to better understand the #fibroticmicroenvironment to unlock key insights for #cancer progression and therapeutic response. 📝 Read the full announcement: https://lnkd.in/eChYqq3j Fibrosis and collagen fibers are emerging #biomarkers in #cancerresearch, linked to disease progression, immune response, and treatment outcomes. Today, their quantification often relies on specialized staining methods or specialized #microscopy techniques. These methods can be time-consuming, labor-intensive, and difficult to scale for large studies. By combining the power of AI with standard #pathology workflows, PathExplore™ Fibrosis is democratizing access to these crucial biomarkers directly from H&E whole slide images. 𝐅𝐚𝐬𝐭 & 𝐒𝐜𝐚𝐥𝐚𝐛𝐥𝐞 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬: Unlike traditional methods that require special stains, complex imaging technology, and additional tissue, PathExplore™ Fibrosis leverages AI to quickly analyze routine H&E-stained slides, enabling large-scale studies and fast #biomarkerdiscovery. 𝐐𝐮𝐚𝐧𝐭𝐢𝐭𝐚𝐭𝐢𝐯𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: The measurement of fibrosis, collagen, and fiber morphology directly from whole-slide images provides an unprecedented level of detail on #tumormicroenvironment features, offering new opportunities to explore tumor biology and therapeutic responses. 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞 𝐰𝐢𝐭𝐡 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝 𝐏𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲 𝐖𝐨𝐫𝐤𝐟𝐥𝐨𝐰𝐬: By working with standard pathology workflows (H&E-stained slides), the algorithm democratizes advanced fibrosis analysis, allowing labs to integrate it easily without additional microscopy equipment or complex preparation techniques. PathExplore™ Fibrosis is for research use only. Not for use in diagnostic procedures

Earlier today our Chief Medical Officer, Eric Walk MD, FCAP participated in the panel 'Advancing Digital and #AIPathology in #PrecisionMedicine: Where Are We Now?' at the Advancing Precision Medicine #APM24 conference in Philadelphia. The panel discussed the rising adoption of digital solutions in pathology and the emergence of new technologies that are driving #biomarker discovery and accelerating algorithm development. #Partnerships remain critical to overcoming barriers for #digitalpathology adoption. #advancingprecisionmedicine #ai #health #cancer #oncology #pathology

📣 PathAI is hiring! Our team is passionate about finding creative solutions in #healthtech to transform the field of #pathology with #artificialintelligence. We are looking for new team members to join us on our mission to improve patient outcomes and fuel #biopharma research 🔬 Our core values: 𝐏atients First We embody a patient-first mindset in everything we do and are committed to meeting the needs of our customers to improve patient outcomes. 𝐀ccountability We set out to accomplish the tasks we commit to and take responsibility for our work, and our actions. 𝐓eam We are One PathAI, all working towards the same goal. We trust our teammates and count on each other to get the job done. 𝐇umility We know all that we do matters, big and small. We value openness, we are accepting of others, and are curious to learn from each other. 𝐀ll 𝐈n We are all passionate about our mission and our passion pushes us to be better every day. Apply today: https://lnkd.in/e8GArtha #opentowork #hiring #leadership #regulatory #regulatoryaffairs #biopharma #biotechsales #biotech #biotechnology #newpositions

🎃 Happy #Halloween from your partners at PathAI! 🎃

Today, we’re proud to announce that Vizia Diagnostics, a GI- specialized #pathology laboratory based in Alpharetta, Georgia, has announced that VIZIA has adopted PathAI’s AISightⓇ Image Management System (IMS) and #AI technology to advance the precision and operational efficiency of its pathology services. 🔗 Discover how PathAI’s #digitaldiagnostics solutions can transform pathology labs in our latest #pressrelease: https://lnkd.in/eRdmMGSH In today’s rapidly evolving pathology landscape, independent labs face increasing pressure to provide timely and accurate assessments. To meet these demands, VIZIA Diagnostics conducted a thorough evaluation of #digitalpathology solutions and selected PathAI’s AISight Image Management System as the ideal platform. AISight’s robust workflow optimization, advanced case management, and broad applicability across various use cases were key factors in the decision. By integrating AISight with algorithm products, VIZIA Diagnostics aims to improve turnaround times for their clients and deliver even higher-quality pathology services. "AISight offers more than just efficiency; it empowers us to lead in the evolving field of #gastrointestinal pathology," said Gregg Costantino, CEO of VIZIA Diagnostics. "By streamlining our workflows and enhancing accuracy, we're able to deliver faster, more precise results for our clients. This collaboration aligns with our commitment to being a flexible and quality-focused partner, providing exceptional service and care in the GI space, and positioning us at the forefront of digital and AI pathology." "The transformative potential of AI and Digital Pathology, coupled with the growing need for business-critical solutions our pathologists and GI providers require, was at the forefront of our decision to adopt this system," added Ed Cochrane, Commercial Director of VIZIA Diagnostics. “PathAI’s platform provides us with unmatched agility and responsiveness for the dynamic landscape of anatomic pathology and our diverse customer base.” #PathAI #AISight #partnership #AIPathology #biotech #biotechpartnership #biotechnologynews #biotechnews AISight is for research use only. Not for use in diagnostic procedures.

PathAI CEO, Andrew Beck is live at the Inaugural #CancerAISymposium hosted by Google Cloud presenting "Transforming Oncology #DrugDevelopment with #AI-Powered Digital #Pathology." Learn more about Andy and our mission to improve patient lives with #AIPathology: https://lnkd.in/eR8dWEWu #digitalpathology #Cancer #Oncology